{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:48:54Z","timestamp":1791571734139,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["humanpathol.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.humpath.2016.07.007","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T18:31:13Z","timestamp":1469644273000},"page":"7-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":146,"special_numbering":"C","title":["PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung"],"prefix":"10.1016","volume":"58","author":[{"given":"Sehui","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaemoon","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dohee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heounjeong","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young A","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8466-9681","authenticated-orcid":false,"given":"Yoon Kyung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doo Hyun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2016.07.007_bb0005","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2016.07.007_bb0010","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"10.1016\/j.humpath.2016.07.007_bb0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/cmi.2010.28","article-title":"Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non\u2013small cell lung cancer","volume":"7","author":"Zhang","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.humpath.2016.07.007_bb0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2016.07.007_bb0025","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2016.07.007_bb0030","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2016.07.007_bb0035","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2016.07.007_bb0040","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2016.07.007_bb0045","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.humpath.2016.07.007_bb0050","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2016.07.007_bb0055","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti\u2013PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2016.07.007_bb0060","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti\u2013PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2016.07.007_bb0065","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.humpath.2016.07.007_bb0070","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/modpathol.2015.63","article-title":"Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status","volume":"28","author":"Koh","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2016.07.007_bb0075","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2015.01.016","article-title":"Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers","volume":"88","author":"Kim","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humpath.2016.07.007_bb0080","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1016\/j.ejca.2015.08.013","article-title":"Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas","volume":"51","author":"Kim","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2016.07.007_bb0085","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/pin.12214","article-title":"Immunohistochemical analysis of the expression of E-cadherin and ZEB1 in non\u2013small cell lung cancer","volume":"64","author":"Matsubara","year":"2014","journal-title":"Pathol Int"},{"key":"10.1016\/j.humpath.2016.07.007_bb0090","first-page":"4095","article-title":"Transcription factors related to epithelial mesenchymal transition in tumor center and margin in invasive lung adenocarcinoma","volume":"7","author":"Maeng","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.humpath.2016.07.007_bb0095","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non\u2013small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.humpath.2016.07.007_bb0100","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1002\/ijc.28925","article-title":"Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non\u2013small cell lung cancer patients with wild-type EGFR","volume":"135","author":"Ren","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2016.07.007_bb0105","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1038\/ncomms6241","article-title":"Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression","volume":"5","author":"Chen","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.humpath.2016.07.007_bb0110","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12943-015-0421-2","article-title":"Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells","volume":"14","author":"Alsuliman","year":"2015","journal-title":"Mol Cancer"},{"key":"10.1016\/j.humpath.2016.07.007_bb0115","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1158\/1078-0432.CCR-15-0876","article-title":"A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition","volume":"22","author":"Mak","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2016.07.007_bb0120","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1158\/0008-5472.CAN-10-2217","article-title":"B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin","volume":"71","author":"Cao","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2016.07.007_bb0125","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1158\/0008-5472.CAN-11-0527","article-title":"Immunoregulatory molecule B7-H1 (CD274) contributes to skin carcinogenesis","volume":"71","author":"Cao","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2016.07.007_bb0130","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s12032-015-0655-2","article-title":"PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma","volume":"32","author":"Wang","year":"2015","journal-title":"Med Oncol"},{"key":"10.1016\/j.humpath.2016.07.007_bb0135","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ccr.2009.01.023","article-title":"Cancer metastasis is accelerated through immunosuppression during snail-induced EMT of cancer cells","volume":"15","author":"Kudo-Saito","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2016.07.007_bb0140","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.semcancer.2012.02.013","article-title":"EMT as the ultimate survival mechanism of cancer cells","volume":"22","author":"Tiwari","year":"2012","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.humpath.2016.07.007_bb0145","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2016.07.007_bb0150","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.lungcan.2011.01.008","article-title":"Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma","volume":"73","author":"Uramoto","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humpath.2016.07.007_bb0155","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2016.07.007_bb0160","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2012.43.3912","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease","volume":"31","author":"Ohashi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2016.07.007_bb0165","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/0008-5472.CAN-05-1988","article-title":"Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines","volume":"66","author":"Witta","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2016.07.007_bb0170","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716301599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716301599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T02:25:35Z","timestamp":1536546335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817716301599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":34,"alternative-id":["S0046817716301599"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2016.07.007","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2016.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}